The realization in the 1990s that allogeneic stem cell transplants (SCT) have a potentially curative graft-versus-leukemia (GVL) effect in addition to the antileukemic action of myeloablative conditioning regimens was a major stimulus for the development of reduced-intensity conditioning (RIC) regimens, aimed primarily at securing engraftment to provide the GVL effect, while minimizing regimen-related toxicity. It is now over 10 years since RIC regimens were heralded as a new direction in the field of SCT. Over the last decade much has been learned about the ways in which the conditioning regimen can be tailored to provide adequate immunosuppression, and modulated to deliver a chosen degree of antimalignant treatment. The huge literature of clinical data with RIC transplantation now permits us to more clearly define the success and limitations of the approach. This review examines the origins of RIC SCT, explores the degree to which the initial expectations and purpose of the approach have been realized, and outlines some ways forward for the field.
Introduction
When clinical bone marrow transplantations (BMT) for leukemia was introduced at the end of the 1960s, pretransplant conditioning regimens were used to deliver myeloablative antileukemic treatment with the immune suppression required to establish engraftment. The cyclophosphamide and total body irradiation (TBI) schedule pioneered by Thomas et al. 1 was a reliable way to achieve these objectives but did not prevent leukemic relapse. 2 Further intensification of conditioning was limited by a concommittent increase in regimen-related mortality (RRM). However, it became clear that allogeneic BMT also had a graft-versus-leukemia (GVL) effect, clearly identifiable in large patient cohorts and related to the infusion of allogeneic lymphocytes. 3 Furthermore, the GVL effect of donor lymphocyte infusion (DLI) was sufficient to eliminate relapsed leukemia following BMT. 4 Origin of reduced-intensity stem cell transplants Given the power of the GVL effect, it became relevant to determine whether reduced-intensity conditioning (RIC) regimens could be used to extend transplantation to elderly or debilitated patients, not normally considered for stem cell transplants (SCT) because of high RRM from a conventional BMT. 5, 6 It was argued that these safer transplants might be performed in the outpatient setting, with cost savings, and justify experimental transplantation seeking a graft-versus-tumor (GVT) effect in patients with metastatic solid tumors. [7] [8] [9] An advantage of RIC transplantation was the possibility of modulating immune recovery by achieving a mixed chimeric state. Experimental transplantion in mice and pigs by Sachs and Sykes in Boston, and in dogs by Storb in Seattle indicated that reduced conditioning and post-transplant immunosuppression resulted in stable mixed chimerism without rejection or GVHD. Furthermore, full donor chimerism could be later restored by a DLI, to provide GVL reactivity. [10] [11] [12] [13] [14] [15] Such experimental models set the stage for RIC transplants in older or debilitated patients with hematological malignancies in Seattle, 13, [16] [17] [18] Boston 19 and Jerusalem. 14, 20, 21 A parallel strategy, introduced by Carella was a tandem autologous-allogeneic transplantation, where the patient's disease was debulked by a myeloablative stem cell autograft, followed after recovery by a RIC transplant to provide the graft-versus-malignancy effect. 22, 23 Thus, in the mid-1990s, transplant groups in the United States and Europe simultaneously introduced RIC regimens in HLA identical related and unrelated donor transplants for older or debilitated patients with hematological malignancies. [24] [25] [26] [27] In the last decade, the RIC approach has been widely adopted by transplant centers worldwide and over 10 000 RIC transplants, many in older individuals, have been reported. This review summarizes the results of RIC transplants in malignant diseases, examines how much the initial ideas and expectations of RIC transplants have been borne out, and defines limitations and future prospects for RIC transplantation.
Overview of RIC regimens
Published data on 39 reduced-intensity regimens used in over 2000 SCT are shown in Table 1 . Of these, 35 (90%) use fludarabine (Flu) (125-240 mg/m 2 ) as part of the conditioning. However, there is great diversity in the nature of the other agents used, and a spectrum of dose intensity from myeloablative regimens to those that are only immunosuppressive. Despite some overlap, regimens can be conveniently grouped into those that are relatively intensive, which employ either busulfan (Bu) at doses up to 10 mg/kg, melphalan (Mel) at doses dose up to 180 mg/m 2 , or (iii) TBI at doses up to 8 Gy. Thiotepa in doses up to 10 mg/kg has also been included in some of these regimens. 63 The least intensive group of regimens employ cyclophosphamide (Cy) or thymic irradiation with various antibody combinations with or without Flu. Low-intensity RIC regimens carry an increased risk of graft failure -for example, up to 17% of patients given low-dose TBI rejected the transplant, 18 but the incidence was decreased to less than 3% with the addition of Flu. 65 Rejection rates for Flu-based grafts are generally less than 3%, suggesting that Flu given at doses between 125 and 150 mg/m 2 plays a central role in the establishment of engraftment in RIC transplantation. Flu, as the immunosuppressive component of the conditioning, has been successfully combined with wide variations in dose and type of partner agents (TBI and alkylating agents being the most popular) to create regimens of different intensity selected for particular indications. Of the alkylating agents, Cy has the most immunosuppressive action, making it a good partner with Flu for intensive immunoablation. Busulfan has emerged as a welltolerated agent, especially by the intravenous route where its bioavailability is better controlled. 29, 34, 35, 66 
Engraftment dynamics
The need to understand engraftment with RIC regimens led to the development of lineage-specific chimerism assays, which have provided insights into the factors that separately regulate lymphoid and myeloid recovery. Using minisatellite probes to define donor and recipient cells sorted by T (CD3), myeloid (CD13/15), B (CD19) and NK lineages (CD56/16) Childs et al. 67 reported a consistent pattern of T-cell engraftment preceeding myeloid engraftment. Donor B cell recovery was concurrent with donor myeloid recovery while grafted NK cells had an intermediate recovery pattern between T-cell and myeloid. Graft-versus-host disease (GVHD) and associated GVL effects only occurred after the establishment of full donor T-cell chimerism. The loss of residual host myeloid cells and B cells was also attributable to a graft-versus-marrow and graft-versus-B cell effect, respectively, revealing a role for donor T cells in myeloablation. This pattern of recovery established the Flu/Cy regimen as being highly immunoablative but not myeloablative, since the hematological recovery following transplant was initially recipient derived. In contrast, the Seattle group, using a low-dose TBI regimen reported the early establishment of donor myeloid engraftment, followed later by T-cell engraftment, demonstrating that the regimen was more myelosuppressive than immunosuppressive. 18, 53 The choice of regimen may also affect immune reconstitution more subtly -Sykes and Spitzer present data suggesting that TLI with thymic irradiation provides tolerance through a mechanism not well understood. 15 Recent promising results using very lowdose TLI regimens attribute the low incidence of GVHD in transplants from donors other than HLA identical siblings to the persistence of host NKT cells with strong tolerizing properties.
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Regimen-related toxicity
The dramatic reduction in the early post-transplant regimenrelated toxicity from RIC transplants is undisputed. Mucositis and veno-occlusive disease are almost nonexistent after RIC transplants and early mortality is much lower than that observed after standard intensity SCT. 100-day mortality rates are also low, but more patients may die in the subsequent 100 days, mainly from GVHD (Tables 2-5), making the 200 day mortality a more reliable estimate of treatment failure. Nevertheless, older transplant recipients have greater co-morbidities and with increased age and disability more patients die from comorbidities not directly associated with their underlying malignancy. The move to transplants in patients in their 6th 7th and even 8th decade has prompted transplanters to develop better ways to evaluate co-morbidity and determine the interaction of recipient frailty with RIC transplant outcome. In Seattle the Charleston comorbidity score applied to RIC transplant recipients has identified a direct relationship between score and outcome, which could help, in addition to the age factor, in improving outcome prediction for the individual. 5, 6, 71 GVHD Acute and chronic GVHD remain the major limitations to the success of RIC transplants in older people. It was hoped that the reduced mucositis induced by the RIC regimen might translate into a reduced severity of GVHD, because of a reduction in the cytokine storm, believed to be initiated by gut-derived endotoxin leaking through damaged mucosa. [72] [73] [74] [75] With this assumption, many investigators using RIC regimens gave only modest immunosuppression post-transplant -for example, single agent cyclosporine 76 or cyclosporine plus mycophenolate mofetil. 18 In the absence of comparative studies with standard regimens given similar post-graft immunosuppression, it is not clear that RIC transplants reduce the risk of GVHD. Recipient age is a further confounding factor: increasing age is associated with greater incidence and severity of GVHD. 77 There are many possible explanations for this -elderly recipients have less ability for tissue repair, they receive transplants from older donors who may have reduced numbers of regulatory T cells SCT with RIC regimen AJ Barrett and BN Savani Tables 2-5 summarize the incidence of acute and chronic GVHD in several recent RIC transplant series in older patients or individuals with comorbidities. The high mortality from grades III-IV acute GVHD has been a stimulus to improve the prevention of this complication. The induction of a mixed T-cell chimerism does reduce GVHD or at least delay it until full chimerism is achieved. 16, 78, 79 However, breaking the tolerant state with DLI can reintroduce the risk of severe GVHD. 18, 80, 81 The administration of alemtuzemab during the preparative regimen is highly effective at reducing GVHD in Flu/Mel transplants. 39, 44, 82, 83 However, the dose and timing of the monoclonal is critical -too much too close to the time of transplant has led to a high incidence of treatment failure from infections (delayed immune reconstitution) or leukemic relapse. [83] [84] [85] Doses of 10 mg given day À7 or À6 before transplant for 5 days appear to achieve better results. 86, 87 Chronic GVHD is the major cause of late mortality after RIC transplants. 18, 25, 43, 88, 89 The incidence of chronic GVHD (Tables 2-5 ) ranges between 40 and 60%, leading to late deaths between 100 and 200 days posttransplant. Again it is difficult to ascribe the chronic GVHD incidence specifically to the use of RIC regimens since most RIC transplants are performed with G-CSF mobilized peripheral blood stem cell transplants (PBSCT), which have a significantly greater propensity to cause chronic GVHD than BMT. 90, 91 Moreover, after RIC transplants, delayed T-cell engraftment leads to development of GVHD after 100 days with features of both acute and chronic GVHD (the so-called 'overlap syndrome'). Alemtuzumab (campath) is also effective at preventing this delayed form of GVHD (Tables 2 and 3) .
Graft-versus-malignancy effects
It is now clear that the hypothesis that RIC transplants could be used to deliver an effective GVL effect is correct. Indeed, the typical delayed regression of malignant disease, long after any effect from the preparative regimen has passed, is proof of principle that RIC transplants exert strong and sometimes curative alloresponses against the recipient's malignancy. The GVL effect after RIC transplants is most marked in CML, 35 chronic lymphocytic leukemia (CLL), 92, 93 mantle cell lymphoma, 49, 61, 94 and low-grade lymphomas. 62, 94 It is also detectible in AML and MDS, 18, 44, 63, 76, 95 multiple myeloma, 22,96-100 and metastatic renal cell carcinoma. 7, 8, 101 It has been described, but is less powerful in ALL, 102, 103 high-grade lymphomas, 94, 104 and other solid tumors including, ovarian carcinoma, 8 breast cancer 8, 9, 23 and possibly pancreatic cancer. 105 Nevertheless, the RIC approach may have less ability to induce prolonged disease-free survivals than standard intensity regimens. For example, relapse rates after RIC regimens for AML are higher than relapse rates in comparable disease subtypes in (somewhat younger) patients receiving standard conditioning regimens. 29, 44, 76, 106 Even in CML, considered to be the most sensitive to GVL effects, the weakly myelosuppressive regimen Flu/Cy achieved disappointing results. In a series of CML patients receiving transplants from identical siblings, 4/5 patients transplanted in second chronic phase died in blast crisis and only 2/7 patients transplanted in first chronic phase achieved molecular remission (MR). The remaining chronic phase patients only achieved MR with multiple DLI, imatinib and interferon, or reconditioning with Cy/TBI 1200 cGy and a second transplant from the original donor (two patients). 60 More favorable results in CML have been reported with the more myelosuppressive Flu/Bu regimen 35, 37 and also with a regimen consisting of dibromomannitol and cytosine arabinoside. 107 It thus appears that some leukemia bulk reduction may be helpful even in leukemias that are exceptionally sensitive to GVL effects. Whether favorable results could be achieved in CML by first reducing leukemia burden with imatinib followed by a nonmyeloablative transplant is unlikely to be known, given current reluctance to transplant older patients with CML who are responsive to this agent.
Results of RIC transplants
Because of the diversity of patients treated and differences in post-transplant management (indication for transplant, choice of donor, type of GVHD prophylaxis, use of DLI), only limited conclusions can be drawn about the relative merits of particular protocols. In Tables 2-5 , results are summarized according to the major regimen categories listed in Table 1 . The median age at transplant ranges from 31 to 59 years but is over 50 in most protocols. The inclusion of younger patients usually implies that they were selected for the RIC protocol because of comorbidities (often includes prior autologous SCT). Most series include family-matched and unrelated donor transplants for most hematological malignancies, but there is an overrepresentation of transplants for myeloid malignancies. The most frequently used GVHD prophylaxis is a standard combination of cyclosporine or tacrolimus with reduced-dose methotrexate. Nevertheless, acute and chronic GVHD incidence varies widely and profoundly impacts the wide spectrum of TRM encountered. There is a trend for the lowest TRM with the least intensive regimen, similar outcomes in TBI-and Bu-based regimens and somewhat higher TRM in Mel-based regimens. Overall survivals at 2 years or more range widely between 20 and 80% with somewhat lower figures for progression-free survival. It can be concluded that RIC regimens can achieve remarkably favorable outcomes in patients who would not normally be considered for SCT, but these regimens suffer from the same limitations as standard intensity transplants -relapse, GVHD and TRM from causes other than the regimen.
Current concerns
When to perform RIC versus standard intensity transplants? While it is clear that RIC transplants have opened the way to using allogeneic SCT in patients several decades older than the upper age limit of 55 years previously used as a cutoff for standard regimens, the superiority of the RIC approach cannot be assumed. Outcomes for standard transplant regimens have generally improved, newer myeloablative regimens of Flu with full-dose intravenous Bu achieve 100 day TRM below 10%, as do some current Cy TBI regimens. [108] [109] [110] [111] While older patients might suffer greater morbidity using such full-dose regimens, their TRM might be offset by lower relapse rates from a more intensive regimen, leading to a disease-free survival comparable to that achieved with less effective but safer RIC regimens. Indeed, some recent nonrandomized comparison of RIC versus standard intensity transplants found that despite lower TRM with RIC regimens, there was a higher relapse rate and comparable survival. 29, 32, [112] [113] [114] These studies were carried out on a heterogeneous patient population. Given the variability of the GVL effect in different disease states, it would be necessary to perform comparisons of higher and lower intensity regimen transplants for specific disease states in order to find the best SCT with RIC regimen AJ Barrett and BN Savani compromise between efficacy and toxicity. Such studies are important because they may reveal that certain conditions with slowly progressive disease (e.g. CLL) are always best treated by RIC regimens, whatever the patient age; while conditions such as advanced MDS may require the maximum tolerated regimen intensity. 115, 116 RIC transplants have shown promises in myeloma, [96] [97] [98] [99] [100] and advanced lymphomas. 49, 61, 62, 94 What is a suitable age-limit for RIC transplants? Advancing age brings increasing risks from comorbidities, irrespective of the choice of transplant regimen. Population statistics indicate that the probability of 5-year survival in individuals aged 60-70 is 80% falling to 60% in the next decade and 50% in individuals over 80 years. To make sensible choices about which older patient to transplant, it is necessary to factor together the inherent age-related mortality of older patients, with the mortality risk of the individual's hematological malignancy.
Future developments

New RIC regimens
A developing area in preparative regimen design is the use of low-toxicity targeted therapies such as imatinib, bortezomib, rituximab to partner with RIC transplants to combine lowtoxicity targeted treatment with a GVL effect. 117, 118, 119 The newer tyrosine kinase inhibitor nilotinib (AMN105) and the Abl/ Src inhibitor dasatinib (BMS 254825) have shown efficacy in imatinib resistant patients with CML 120 and might be useful to combine with RIC transplants as salvage treatment. The use of radiolabelled bone marrow seeking antibodies to target the leukemia is another strategy that could be usefully combined with RIC transplants.
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RIC transplants as a platform for controlled immune reconstitution
Promising GVHD preventive therapy with sirolimus, pentostatin and photopheresis deserves exploration in RIC transplants as a more effective means of preventing GVHD. Much recent interest has focused on the potential of CD4 þ CD25 þ regulatory T cells (T REG ) to suppress alloreacting T cells, and animal models indicate that this subset (which comprises o10% of circulating T cells in man) is extremely effective in preventing GVHD. Recently, Karakhanova et al. have developed a strategy to expand T REG with IL-2 and IL-15 bringing closer the possibility of using T REG to prevent GVHD. 122 It is not clear, however, that such improvements in GVHD can be achieved without a reduction in the GVL effect. New strategies are needed that control GVHD without compromising immunity to infection and the graft-versus-malignancy effect. Temporary depletion of dendritic cells (DC) by antibodies may be one way to achieve this. CMRF-44, a mouse monoclonal IgM can be used to specifically eliminate human DC. 123 A humanized antibody is being developed that could be used as an alternative to alemtuzumab in conditioning for SCT. The use of RIC transplants as a platform to enhance the GVL effect requires the selective prevention of GVHD without immunosuppression, so as to allow full immune recovery and an unmodulated GVL effect. Several approaches are already in clinical trial: Bonini's group 124 working with HLA mismatched donor-recipient pairs has transfected donor T lymphocytes with a retroviral vector expressing the herpes simplex virus-thymidine kinase (TK) gene, which confers sensitivity to ganciclovir. The infusion of donor lymphocytes without immunosuppression permits a GVL effect while at the onset of significant GVHD, the administration of ganciclovir prevents GVHD progression by removing T cells carrying the suicide gene. We and others have prepared SCT depleted of GVHD reactivity by removing donor cells reacting to patient lymphocytes with an anti-CD25 immunotoxin. 125 Our results suggest that allodepletion of donor cells ex vivo is clinically feasible in older patients and may reduce the rate of severe acute GVHD. This technique should permit the safe withholding of immunosuppression, thereby facilitating an unrestricted immune response to the malignancy. Furthermore, a fully reconstituted, selectively depleted T-cell repertoire in the absence of immunosuppression, would allow the use of tumor vaccines in the early post-transplant period to further boost GVL effects. The development of peptide vaccines targeting leukemia such as PR1 and WT1 may eventually be used to boost GVL effects after RIC transplants.
Summary and conclusions
The introduction of RIC SCT to treat patients with hematological malignancies has revolutionized the field of SCT and has salvaged patients, who would hitherto have died from diseaseprogression without a transplant. The GVL effect is discernable in a variety of myeloid and lymphoid malignancies and RIC regimens can be successful in patients up to their 7th decade and in those with significant comorbidities. While the RRM is very low, the hope that GVHD would be better tolerated has not been borne out. Consequently, GVHD and disease relapse have emerged as the major limitations of RIC transplants and methods to separate GVHD from GVL are as relevant to RIC as to standard transplants. While it would be helpful to fully evaluate RIC SCT by comparison with standard SCT, there is little likelihood that informative trials will be performed because RIC transplants are largely applied to a different patient population that standard SCT. Furthermore, accumulating favorable experience with Flu-based regimens of all intensities adds justification to the argument that the revolution in conditioning regimens of the last decade is more to do with the use of purine analogbased regimens than the degree of regimen intensity per se.
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Rather than attempt to compare standard with RIC transplants, it may now be timely to cautiously explore dose escalation with Flu-based regimens in older patients at high risk of relapse to find the best balance between disease control and regimenrelated morbidity. The development of comorbidity scoring to predict transplant outcome offers the opportunity to more accurately select the older patient group most likely to suffer from morbidity and mortality after transplantation. This score could be used in future to select regimen intensity according to the patient's frailty rather than to biological age. Meanwhile, better prevention of GVHD and optimization of GVL awaits success with selective allodepletion approaches now being explored in both standard and RIC transplants.
